Drug and Therapeutics Bulletin 1999;37:1-3; doi:10.1136/dtb.1999.3711
Copyright © 1999 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

{blacktriangledown}Mirtazapine - another new class of antidepressant

Relevant BNF section: 4.3.1

{blacktriangledown}Mirtazapine (Zispin-Organon) was introduced in 1997 as "the first noradrenergic and specific serotonergic antidepressant" (or 'NaSSA'). The manufacturer claims that mirtazapine is "effective in all types of depression", with "minimal serotonergic, anticholinergic and antiadrenergic side-effects", "low propensity for interactions", and lower likelihood of relapse during maintenance treatment than with amitriptyline. Is mirtazapine an advance on existing drugs?






About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 1999 BMJ Publishing Group Ltd.